CoChat

Engineering the AAV capsid to evade immune responses

Open access
Barnes, Christopher, Scheideler, Olivia, Schaffer, David · 2019 · Current Opinion in Biotechnology
Cited by 102

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Gene therapy is progressively emerging as a promising and powerful therapeutic modality, and adeno-associated virus (AAV) is a major delivery vehicle for such therapies. Among the most significant challenges that limit AAV’s utility, however, is the immune response it elicits. Antibodies elicited by prior exposure to natural virus or vector can bind to an AAV vector, preventing it from entering the cell. Furthermore, even if AAV manages to infect a target cell, these cells can then be attenuated by lymphocytes. Improvements in our understanding of how the immune system responds to AAV have guided engineering of the capsid to reduce those responses, yielding capsid variants that are much stealthier and more effective. This review summarizes recent advances in understanding the immune response to AAV as well as highlights engineering methods that enhance AAV’s potential as a gene therapy vector.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.copbio.2019.01.002

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 8

  1. Tenenbaum, 2003, Evaluation of risks related to the use of adeno-associated virus-based vectors, Curr Gene Ther, 3, 545, 10.2174/1566523034578131 · DOI · Paper page
  2. Tseng, 2016, Generation and characterization of anti-adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies, J Virol Methods, 236, 105, 10.1016/j.jviromet.2016.07.009 · DOI · Paper page
  3. Varadi, 2012, Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors, Gene Ther, 19, 800, 10.1038/gt.2011.143 · DOI
  4. Kienle, 2012, Engineering and evolution of synthetic Adeno-Associated Virus (AAV) gene therapy vectors via DNA family shuffling, J Vis Exp: JoVE, 62, e3819
  5. Voigt, 2002, Protein building blocks preserved by recombination, Nat Struct Mol Biol, 9, 553
  6. Meliani, 2017, Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors, Blood Adv, 1, 2019, 10.1182/bloodadvances.2017010181 · DOI · Paper page
  7. György, 2017, Rescue of hearing by gene delivery to inner-ear hair cells using exosome-associated AAV, Mol Ther, 25, 379, 10.1016/j.ymthe.2016.12.010 · DOI · Paper page
  8. Bey, 2017, Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders, Gene Ther, 24, 325, 10.1038/gt.2017.18 · DOI

Cited by

Metadata

Authors
Barnes, C., Scheideler, O., & Schaffer, D.
Venue
Current Opinion in Biotechnology
Publisher
Elsevier BV
Published
2019-12
Volume
60
Pages
99-103
ISSN
0958-1669 (ISSN-L)
OpenAlex
W2947082286
Cited by
102
References
29
FWCI
1.44
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
NIH (1R21EB021572)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.